Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals

Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RYTM stock, giving a Buy rating yesterday.

Whitney Ijem has given his Buy rating due to a combination of factors, primarily focusing on the future potential of Rhythm Pharmaceuticals’ pipeline programs. Despite a slight miss in product revenue, attributed to seasonal inventory fluctuations, the company’s overall commercial dynamics remain robust and on track.
Importantly, the progress in regulatory filings, such as the supplemental New Drug Application for setmelanotide with the FDA and the Type II variation request to the EMA, is proceeding as planned, which is a positive indicator. Additionally, the anticipated data releases for bivamelagon and RM-718 later in the year are expected to provide further insights into the company’s growth prospects. These developments underpin the confidence in maintaining a Buy rating.

In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $73.00 price target.

RYTM’s price has also changed slightly for the past six months – from $63.900 to $64.630, which is a 1.14% increase.